Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412184 | 0.88 | LMNA (0.35) | LMNAKMT2AAPPALOX5APFEN1 | |
| SCHEMBL3408531 | 0.78 | ALDH1A1 (0.39) | LMNAKMT2ACYP1A2 | |
| SCHEMBL3409060 | 0.75 | KEAP1 (0.40) | LMNAKMT2AAPPALOX5APFEN1 | |
| SCHEMBL3412067 | 0.75 | LMNA (0.39) | LMNAKMT2AAPPALOX5APFEN1 | |
| SCHEMBL14008534 | 0.73 | ALDH1A1 (0.40) | LMNAKMT2A | |
| SCHEMBL3005773 | 0.73 | LMNA (0.40) | LMNAKMT2A | |
| SCHEMBL4996633 | 0.72 | CFTR (0.39) | LMNAKMT2A | |
| SCHEMBL3412056 | 0.72 | ALDH1A1 (0.39) | LMNAKMT2AAPPCYP1A2 | |
| SCHEMBL13532052 | 0.71 | RORC (0.41) | LMNAKMT2ACYP1A2 | |
| SCHEMBL3414451 | 0.70 | LMNA (0.43) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262795-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110844-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2009-09-11 | — | — | WO | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | CHRM1, CHRM2, CHRM3 | LMNA 2488/4885KMT2A 2088/4885APP 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.